Alrg - 500 Beiträge pro Seite
eröffnet am 16.03.03 15:29:49 von
neuester Beitrag 21.03.03 02:34:11 von
neuester Beitrag 21.03.03 02:34:11 von
Beiträge: 11
ID: 708.366
ID: 708.366
Aufrufe heute: 0
Gesamt: 326
Gesamt: 326
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| heute 16:23 | 3319 | |
| heute 15:47 | 3222 | |
| vor 31 Minuten | 1723 | |
| vor 9 Minuten | 1495 | |
| vor 5 Minuten | 1375 | |
| vor 1 Stunde | 1273 | |
| vor 37 Minuten | 1253 | |
| heute 15:09 | 1232 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.001,60 | +0,59 | 240 | |||
| 2. | 2. | 168,20 | +0,08 | 87 | |||
| 3. | 3. | 9,7000 | +12,27 | 75 | |||
| 4. | 14. | 6,1400 | -1,35 | 69 | |||
| 5. | 11. | 0,1865 | 0,00 | 52 | |||
| 6. | 7. | 0,8750 | -12,50 | 47 | |||
| 7. | 12. | 0,1561 | +2,97 | 38 | |||
| 8. | 6. | 2.302,50 | 0,00 | 36 |
Feedback
http://translate.google.com/translate?hl=de&sl=en&u=http://m… Was haltet Ihr von der Firma???????? FONX
http://quotes.barchart.com/texadv.htx?sym=alrg Sieht doch gar nicht schlecht aus,oder nicht???????? FONX
http://www.knobias.com/individual/public/news.htm?eid=3.1.0e… Wenn jemand was damit anfangen kann!!!!!!!!! FONX
http://finance.lycos.com/home/stocks/charts.asp?symbols=BB%3… 200% in einem Jahr,aber wie geht es weiter???????????FONX
Trading Spotlight
ALRG
ALLERGY RESEARCH GROUP INC
0.300
+0.120 +66.67%
Daily Commentary
BUY
Our system recommends BUY as of today. Previous SELL recommendation was made on 1/30/2003 (43) days ago, when the stock price was 0.210. Since then the stock gained 42.86% .
Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. A bullish gap occured, which may indicate an upward break out.The volume is extremely high. The security price is trending up and is overbought.
There is a strong upward move that turned up all the moving averages. This may be a sign of a new uptrend. It is still not too late to buy this stock.
Click here to get a full trend analysis of this stock Candlestick Analysis
Today’s Candlestick Patterns:
Long White Candlestick
Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!
Stock Quote
Last 0.300
Previous Close 0.180
Change +0.120
% Change +66.67%
Volume 100,500
Stock Activity
Open 0.260
Day`s High 0.320
Day`s Low 0.193
52 Week High 0.340
52 Week Low 0.100
Stock Price History
3 Month % Change 25.00
6 Month % Change -9.09
12 Month % Change 200.00
Stock Statistics
50 Day Close MA 0.201
200 Day Close MA 0.226
65 Day Volume MA 7,566
JS200
ALLERGY RESEARCH GROUP INC
0.300
+0.120 +66.67%
Daily Commentary
BUY
Our system recommends BUY as of today. Previous SELL recommendation was made on 1/30/2003 (43) days ago, when the stock price was 0.210. Since then the stock gained 42.86% .
Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. A bullish gap occured, which may indicate an upward break out.The volume is extremely high. The security price is trending up and is overbought.
There is a strong upward move that turned up all the moving averages. This may be a sign of a new uptrend. It is still not too late to buy this stock.
Click here to get a full trend analysis of this stock Candlestick Analysis
Today’s Candlestick Patterns:
Long White Candlestick
Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!
Stock Quote
Last 0.300
Previous Close 0.180
Change +0.120
% Change +66.67%
Volume 100,500
Stock Activity
Open 0.260
Day`s High 0.320
Day`s Low 0.193
52 Week High 0.340
52 Week Low 0.100
Stock Price History
3 Month % Change 25.00
6 Month % Change -9.09
12 Month % Change 200.00
Stock Statistics
50 Day Close MA 0.201
200 Day Close MA 0.226
65 Day Volume MA 7,566
JS200
Allergy Research Group, Inc. Reports Profits For 2002
Friday , March 14, 2003 14:23 ET
HAYWARD, Calif., Mar 14, 2003 (BUSINESS WIRE) -- Allergy Research Group, Inc. (OTCBB:ALRG) today announced financial results for the year ending December 31, 2002.
ALRG recorded total revenue of $12,684,413 for the year, up 8% from 2001. The increase of $935,214 is primarily due to increased marketing efforts and the introduction of new products.
"We are encouraged by the increase in sales which is instrumental in meeting our financial goals," said Chief Executive Officer and Chairman, Dr. Stephen A. Levine, Ph.D., who has implemented a strategy that includes cost controls, the development of a comprehensive management team, increased sales and marketing efforts and reduction of debt.
Cost of sales increased $480,016 to $7,587,795 for the year ended December 31, 2002, compared to $7,107,779 for the year ended December 31, 2001, a corresponding increase resulting from the increase in sales. Gross profit margins increased approximately .7%, approximating 40.2% for 2002 resulting from the higher margins associated with retail sales.
During the period ended December 31, 2002, the Company recorded net income of $997,862, as compared to net income of $326,557 for the period ended December 31, 2001. The increase is a reflection of the increase in sales, higher profit margins, a reduction in selling and general and administrative expenses, from $4,070,974 in 2001 to $3,924,080 in 2002 and a reduction of interest expense. Interest expense decreased approximately $122,393 for the year ended December 31, 2002, as compared to December 31, 2001 due to declining interest rates and the reduction of our outstanding line of credit to zero during the fourth quarter of 2002.
Complete copies of the company`s financial statements, including notes to the financials, can be found on its website at www.nutricology.com.
About Allergy Research Group, Inc.
Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.
Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management`s beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company`s financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company`s filings with the Securities and Exchange Commission, copies of which are available upon request from the Company`s investor relations department.
CONTACT: Allergy Research Group, Inc.
Clinton Abbott, 888/607-5399 (Investor Relations)
URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2003 Business Wire. All rights reserved.
-0-
KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: MEDICAL
EARNINGS
SOURCE:
Allergy
Research
Group,
Inc.
STOCK SYMBOLS: [(alrg)]
JS200
Friday , March 14, 2003 14:23 ET
HAYWARD, Calif., Mar 14, 2003 (BUSINESS WIRE) -- Allergy Research Group, Inc. (OTCBB:ALRG) today announced financial results for the year ending December 31, 2002.
ALRG recorded total revenue of $12,684,413 for the year, up 8% from 2001. The increase of $935,214 is primarily due to increased marketing efforts and the introduction of new products.
"We are encouraged by the increase in sales which is instrumental in meeting our financial goals," said Chief Executive Officer and Chairman, Dr. Stephen A. Levine, Ph.D., who has implemented a strategy that includes cost controls, the development of a comprehensive management team, increased sales and marketing efforts and reduction of debt.
Cost of sales increased $480,016 to $7,587,795 for the year ended December 31, 2002, compared to $7,107,779 for the year ended December 31, 2001, a corresponding increase resulting from the increase in sales. Gross profit margins increased approximately .7%, approximating 40.2% for 2002 resulting from the higher margins associated with retail sales.
During the period ended December 31, 2002, the Company recorded net income of $997,862, as compared to net income of $326,557 for the period ended December 31, 2001. The increase is a reflection of the increase in sales, higher profit margins, a reduction in selling and general and administrative expenses, from $4,070,974 in 2001 to $3,924,080 in 2002 and a reduction of interest expense. Interest expense decreased approximately $122,393 for the year ended December 31, 2002, as compared to December 31, 2001 due to declining interest rates and the reduction of our outstanding line of credit to zero during the fourth quarter of 2002.
Complete copies of the company`s financial statements, including notes to the financials, can be found on its website at www.nutricology.com.
About Allergy Research Group, Inc.
Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.
Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management`s beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company`s financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company`s filings with the Securities and Exchange Commission, copies of which are available upon request from the Company`s investor relations department.
CONTACT: Allergy Research Group, Inc.
Clinton Abbott, 888/607-5399 (Investor Relations)
URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2003 Business Wire. All rights reserved.
-0-
KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: MEDICAL
EARNINGS
SOURCE:
Allergy
Research
Group,
Inc.
STOCK SYMBOLS: [(alrg)]
JS200
Bin echt gespannt wie sie weiterläuft?????? Oder auch nur ne Klitsche ,wie viele andere???????? Keine Kaufempfehlung!!!!!!!!! Viel Spaß noch allen !!! FONX
Performance (%-changes)
1 week: 100.00% !!!!!!!!!
1 month: 56.52%
1 year: 242.85%
Nur das Volumen war nicht so toll,aber ansonsten,net schlecht,gelle,Fonx
1 week: 100.00% !!!!!!!!!
1 month: 56.52%
1 year: 242.85%
Nur das Volumen war nicht so toll,aber ansonsten,net schlecht,gelle,Fonx
ALRG Quote
2:24 PM ET
(delayed 15 min.)
0.4000
+0.0400 (+11.11%)
Volume: 6,100
- - - - -
Full quote »
Nicht das Hammervolumen,aber wieder über 11%%%%%% FONX
2:24 PM ET
(delayed 15 min.)
0.4000
+0.0400 (+11.11%)
Volume: 6,100
- - - - -
Full quote »
Nicht das Hammervolumen,aber wieder über 11%%%%%% FONX
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 127 | ||
| 87 | ||
| 47 | ||
| 28 | ||
| 27 | ||
| 24 | ||
| 18 | ||
| 13 | ||
| 12 | ||
| 12 |
| Wertpapier | Beiträge | |
|---|---|---|
| 11 | ||
| 11 | ||
| 9 | ||
| 9 | ||
| 8 | ||
| 8 | ||
| 8 | ||
| 6 | ||
| 6 | ||
| 6 |
